Plasma @entity1425 modulates alpha 1-adrenoceptor mediated pressor responses and the baroreflex control in XXXX with borderline @entity101 .

@entity1 @entity101 @entity1425 @entity34865 @entity2647 @entity1063
Plasma level of @entity1425 has been reported to be elevated in borderline @entity101 . However, its role in developing and maintaining @entity101 is still not completely understood. This study aimed to estimate the role of plasma @entity1425 in developing @entity101 . Ten @entity1 with borderline @entity101 (BHT) and 10 age-matched normotensive subjects were included. We infused at least three graded doses of @entity2647 , an alpha-adrenoceptor agonist, into the antecubital vein of subjects lying quietly in a supine position. Mean blood pressure was measured continuously through the right radial artery. Cardiac output was measured by the thermodilution method before and after the administration of each dose of @entity2647 infusion. We obtained dose-response curves for mean blood pressure and total peripheral resistance to @entity2647 . Baroreflex sensitivity was calculated by plotting the longest R-R intervals against the elevated peak mean blood pressure after the infusion of each dose of @entity2647 . Plasma @entity1063 and @entity1425 concentrations at rest were measured by high performance liquid chromatography coupled with @entity34865 fluorimetric detection. The plasma @entity1425 level at rest was higher in @entity1 with BHT than in normotensive subjects. With graded infusion of @entity2647 , both the pressor responses and the changes in total peripheral resistance were greater in @entity1 with BHT than in normotensive subjects. The plasma @entity1425 level was positively correlated with the slope of dose response curves for the increments of mean blood pressure to @entity2647 (r = 0.60, p < 0.01). Baroreflex sensitivity was reduced in @entity1 with BHT as compared with normotensive subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
